$VNRX
VolitionRX Ltd Stock $vnrx

$vnrx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000147793223003240 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$216.3K	$149.8K	$119.7K
YoY Change	444.15%	31.17%	740.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.314M	$4.289M	$4.186M
YoY Change	-11.23%	5.7%	-19.4%
% of Gross Profit
Research & Development	$5.451M	$4.906M	$3.637M
YoY Change	66.23%	42.46%	8.1%
% of Gross Profit
Depreciation & Amortization	$288.3K	$250.9K	$249.0K
YoY Change	27.91%	23.93%	5.11%
% of Gross Profit
Operating Expenses	$9.765M	$9.195M	$8.130M
YoY Change	19.98%	18.02%	-7.6%
Operating Profit	-$9.549M	-$9.045M
YoY Change	17.9%	17.82%
Interest Expense	-$31.21K	$6.330K	$9.930K
YoY Change	20.18%	-84.57%	-128.42%
% of Operating Profit
Other Income/Expense, Net	-$2.241K	$172.1K	$664.6K
YoY Change	-100.57%	-519.5%	-6.63%
Pretax Income	-$9.551M	-$8.873M	-$7.336M
YoY Change	23.53%	14.96%	-9.52%
Income Tax
% Of Pretax Income
Net Earnings	-$9.551M	-$8.780M	-$7.242M
YoY Change	23.53%	13.75%	-9.87%
Net Earnings / Revenue	-4415.55%	-5860.53%	-6049.2%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.14	-$0.15	-$0.13
COMMON SHARES
Basic Shares Outstanding	63.18M shares	63.10M shares	57.52M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.74M	$10.01M	$10.87M
YoY Change	18.01%	-57.82%	-47.2%
Cash & Equivalents	$19.74M	$10.01M	$10.87M
Short-Term Investments
Other Short-Term Assets	$542.6K	$716.9K	$447.6K
YoY Change	-44.29%	-66.69%	-43.1%
Inventory
Prepaid Expenses	$1.025M	$1.111M	$784.9K
Receivables	$196.5K	$118.6K	$72.61K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$21.51M	$11.96M	$12.17M
YoY Change	15.33%	-53.93%	-44.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.455M	$5.402M	$5.393M
YoY Change	13.47%	14.42%	9.81%
Goodwill
YoY Change
Intangibles	$67.72K	$90.83K	$110.5K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.054M	$6.086M	$6.123M
YoY Change	6.24%	6.27%	11.09%
TOTAL ASSETS
Total Short-Term Assets	$21.51M	$11.96M	$12.17M
Total Long-Term Assets	$6.054M	$6.086M	$6.123M
Total Assets	$27.56M	$18.04M	$18.30M
YoY Change	13.2%	-43.05%	-33.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.493M	$2.989M	$3.043M
YoY Change	34.22%	35.56%	97.28%
Accrued Expenses	$3.391M	$2.719M	$2.872M
YoY Change	4.77%	-28.21%	-24.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.199M	$1.121M	$1.067M
YoY Change	10.53%	-21.16%	33.7%
Total Short-Term Liabilities	$18.80M	$17.24M	$17.39M
YoY Change	8.37%	-1.57%	166.83%
LONG-TERM LIABILITIES
Long-Term Debt	$2.452M	$2.549M	$2.779M
YoY Change	40.68%	-7.83%	22.39%
Other Long-Term Liabilities	$340.3K	$381.7K	$400.1K
YoY Change	-34.49%	-35.78%	84.11%
Total Long-Term Liabilities	$2.452M	$2.549M	$2.779M
YoY Change	40.68%	-24.13%	22.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.80M	$17.24M	$17.39M
Total Long-Term Liabilities	$2.452M	$2.549M	$2.779M
Total Liabilities	$22.44M	$21.02M	$21.42M
YoY Change	10.73%	2.23%	119.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$185.5M	-$176.0M	-$167.3M
YoY Change	21.83%		22.1%
Common Stock	$78.14K	$63.11K	$57.87K
YoY Change	45.11%		7.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.844M	-$2.336M	-$3.127M
YoY Change
Total Liabilities & Shareholders Equity	$27.56M	$18.04M	$18.30M
YoY Change	13.2%	-43.05%	-33.45%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$9.551M	-$8.780M	-$7.242M
YoY Change	23.53%	13.75%	-9.87%
Depreciation, Depletion And Amortization	$288.3K	$250.9K	$249.0K
YoY Change	27.91%	23.93%	5.11%
Cash From Operating Activities	-$7.348M	-$8.745M	-$5.183M
YoY Change	17.27%	-392.48%	17.55%
INVESTING ACTIVITIES
Capital Expenditures	$301.4K	$200.6K	$578.7K
YoY Change	-155.68%	60.93%	-550.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$301.4K	-$200.6K	-$578.7K
YoY Change	-44.32%	60.93%	350.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$223.3K
YoY Change		-10.92%
Cash From Financing Activities	17.34M	$8.147M	305.4K
YoY Change	-3867.97%	2124.85%	-85.44%
NET CHANGE
Cash From Operating Activities	-7.348M	-$8.745M	-5.183M
Cash From Investing Activities	-301.4K	-$200.6K	-578.7K
Cash From Financing Activities	17.34M	$8.147M	305.4K
Net Change In Cash	9.691M	-$856.2K	-5.456M
YoY Change	-233.36%	-127.17%	123.58%
FREE CASH FLOW
Cash From Operating Activities	-$7.348M	-$8.745M	-$5.183M
Capital Expenditures	$301.4K	$200.6K	$578.7K
Free Cash Flow	-$7.649M	-$8.945M	-$5.762M
YoY Change	33.63%	-412.21%	34.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Revenues Revenues	149808	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4905678	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3590053	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2602152	usd
CY2023Q1	vnrx	Current Portion Of Grant Repayable CurrentPortionOfGrantRepayable	42382	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	17237912	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2549116	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	429977	usd
CY2023Q1	vnrx	Grant Repayable Net Of Current Portion GrantRepayableNetOfCurrentPortion	425951	usd
CY2023Q1	us-gaap	Liabilities Liabilities	21024678	usd
CY2022Q4	vnrx	Grant Repayable Net Of Current Portion GrantRepayableNetOfCurrentPortion	420466	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21422016	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63111766	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57873379	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8779548	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	224310	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	62585	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	65361	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000093314
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63111766	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57873379	shares
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	223340	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	250711	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11445	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	13133	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36833
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	VOLITIONRX LIMITED
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1949078
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1489 West Warm Springs Road
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 110
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89014
CY2023Q1	dei	City Area Code CityAreaCode	646
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	650–1351
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	VNRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63179837	shares
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	381722	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	400091	usd
CY2023Q1	vnrx	Service Revenue ServiceRevenue	5356	usd
CY2022Q1	vnrx	Service Revenue ServiceRevenue	60254	usd
CY2023Q1	vnrx	Product Revenue ProductRevenue	144452	usd
CY2022Q1	vnrx	Product Revenue ProductRevenue	53957	usd
CY2022Q1	us-gaap	Revenues Revenues	114211	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2581703	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1707457	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1598983	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	9194838	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7791188	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9045030	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7676977	usd
CY2023Q1	vnrx	Income From Grants IncomeFromGrants	165795	usd
CY2022Q1	vnrx	Income From Grants IncomeFromGrants	0	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	57648	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	2	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	51322	usd
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	41032	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	172121	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41030	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-8872909	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-7718007	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-93361	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-83977	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7634030	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-56478	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-117904	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8929387	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7835911	usd
CY2023Q1	vnrx	Net Loss Per Share Basic And Diluted Attributable To Volitionrx Limited NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited	-0.15
CY2022Q1	vnrx	Net Loss Per Share Basic And Diluted Attributable To Volitionrx Limited NetLossPerShareBasicAndDilutedAttributableToVolitionrxLimited	-0.14
CY2023Q1	vnrx	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	60176975	shares
CY2022Q1	vnrx	Weighted Average Number Of Common Share Outstanding Basic And Diluted WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted	53775096	shares
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8427654	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	693657	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-8872909	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17722105	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9467	usd
CY2022Q1	vnrx	Common Stock Issued For Settlement Of Rsu S Amount CommonStockIssuedForSettlementOfRsuSAmount	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	915031	usd
CY2022Q1	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-117904	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-7718007	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10810692	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-8872909	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-7718007	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	271990	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	693657	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	915031	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	253447	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	664782	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	118592	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59861	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	269344	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	102185	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10000000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-206562	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	981786	usd
CY2023Q1	vnrx	Increase Decrease In Management And Directors Fees Payable IncreaseDecreaseInManagementAndDirectorsFeesPayable	9019	usd
CY2022Q1	vnrx	Increase Decrease In Management And Directors Fees Payable IncreaseDecreaseInManagementAndDirectorsFeesPayable	25750	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-61141	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-57008	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8744744	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3610395	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	200592	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124648	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200592	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-124648	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8427655	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9467	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14336	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	31772	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8146762	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-57598	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-80304	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-856172	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3151066	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10867050	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20581313	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10010878	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23732379	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	51322	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	41009	usd
CY2023Q1	vnrx	Common Stock Issued On Cashless Exercises Of Stock Options And Warrants CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrants	27	usd
CY2022Q1	vnrx	Common Stock Issued On Cashless Exercises Of Stock Options And Warrants CommonStockIssuedOnCashlessExercisesOfStockOptionsAndWarrants	15	usd
CY2023Q1	vnrx	Offering Costs From Issuance Of Common Stock OfferingCostsFromIssuanceOfCommonStock	195892	usd
CY2022Q1	vnrx	Offering Costs From Issuance Of Common Stock OfferingCostsFromIssuanceOfCommonStock	0	usd
CY2023Q1	vnrx	Non Cash Note Payable NonCashNotePayable	356258	usd
CY2022Q1	vnrx	Non Cash Note Payable NonCashNotePayable	620549	usd
CY2023Q1	vnrx	Amount Held In Money Market Account AmountHeldInMoneyMarketAccount	3300000	usd
CY2023Q1	vnrx	Covid19 Pandemic Impact Policy Textblock COVID19PandemicImpactPolicyTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of the date of this filing, global economies continue to experience volatility in the wake of the COVID-19 pandemic. As a result of the pandemic, the Company previously experienced disruptions to its clinical trials, including patient enrollment and sample collection delays.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic and the related developments, the extent to which the pandemic may impact its business, financial condition, and results of operations in future periods is uncertain and will be affected by a number of factors outside of the Company’s control.</p>
CY2023Q1	vnrx	Common Stock Share Authorized CommonStockShareAuthorized	100000000	shares
CY2023Q1	vnrx	Common Stock Price Per Sahres CommonStockPricePerSahres	0.001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63111766	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57873379	shares
CY2023Q1	vnrx	Common Stock Shares Expired CommonStockSharesExpired	125000	shares
CY2023Q1	vnrx	Weighted Average Remaining Contractual Life WeightedAverageRemainingContractualLife	P3Y11M1D
CY2023Q1	vnrx	Compensation Expense Rsus CompensationExpenseRsus	112325	shares
CY2023Q1	vnrx	Rsu Expense RsuExpense	193199	usd
CY2023Q1	vnrx	Equity Incentive Rsu EquityIncentiveRsu	34000	shares
CY2023Q1	vnrx	Incentive Rsu Issued IncentiveRsuIssued	26978	shares
CY2023Q1	vnrx	Rsus Held For Taxes RsusHeldForTaxes	7022	usd
CY2023Q1	vnrx	Operating Leases Future Minimum Payment Due Current OperatingLeasesFutureMinimumPaymentDueCurrent	27794	usd
CY2023Q1	vnrx	Operating Leases Future Minimum Payment Due In Two Years OperatingLeasesFutureMinimumPaymentDueInTwoYears	4055	usd
CY2023Q1	vnrx	Operating Leases Future Minimum Lease Payment Due OperatingLeasesFutureMinimumLeasePaymentDue	31849	usd
CY2023Q1	vnrx	Grant Repyable GrantRepyable	468333	usd
CY2023Q1	vnrx	Long Term Debt Payable LongTermDebtPayable	3670185	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	986465	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1153075	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	713500	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	486624	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	285276	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	452628	usd
CY2023Q1	vnrx	Long Term Debt Due LongTermDebtDue	4077568	usd
CY2023Q1	vnrx	Long Term Debt Less Amount Representing Interest LongTermDebtLessAmountRepresentingInterest	-407383	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	3670185	usd
CY2023Q1	vnrx	Payments For Future Research And Collobration PaymentsForFutureResearchAndCollobration	959406	usd
CY2023Q1	vnrx	Future Minimum Collaborative Agreement Obligations Of Fiscal Year FutureMinimumCollaborativeAgreementObligationsOfFiscalYear	877633	usd
CY2023Q1	vnrx	Future Minimum Collaborative Agreement Obligations Of Fiscal Year One To Five FutureMinimumCollaborativeAgreementObligationsOfFiscalYearOneToFive	81773	usd
CY2023Q1	vnrx	Collaborative Agreement Obligations CollaborativeAgreementObligations	959406	usd
CY2020Q4	vnrx	Aggerate Amount Payable Description AggerateAmountPayableDescription	under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million
CY2023Q1	vnrx	Amount Repayable AmountRepayable	143550	usd
CY2023Q1	vnrx	Payable By Company For Services Rendered PayableByCompanyForServicesRendered	2173569	usd
CY2023Q1	vnrx	First Insurance Funding Amount FirstInsuranceFundingAmount	356258	usd
CY2023Q1	vnrx	Fixed Interest Rate FixedInterestRate	0.0742	pure
CY2023Q1	vnrx	Line Of Credit Facility Expiration Dates One LineOfCreditFacilityExpirationDatesOne	November 2023
CY2023Q1	vnrx	Insurance Principal Balance Payable InsurancePrincipalBalancePayable	316673	usd
CY2023Q1	vnrx	Stock Option Granted Shares StockOptionGrantedShares	1000000	shares
CY2023Q1	vnrx	Restricted Stock Option Granted Shares RestrictedStockOptionGrantedShares	500000	shares
CY2023Q1	vnrx	Accrued Compensation Expense AccruedCompensationExpense	726048	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	494485	usd
CY2023Q1	vnrx	Amortised Of Outstanding Award Amount One AmortisedOfOutstandingAwardAmountOne	248624	usd
CY2023Q1	vnrx	Amortised Of Outstanding Award Amount AmortisedOfOutstandingAwardAmount	245861	usd
CY2023Q1	vnrx	Un Amortised Of Outstanding Award UnAmortisedOfOutstandingAward	1159695	usd

Files In Submission

Name	View Source	Status
vnrx-20230331_cal.xml	Edgar Link	unprocessable
vnrx-20230331_lab.xml	Edgar Link	unprocessable
0001477932-23-003240-index-headers.html	Edgar Link	pending
0001477932-23-003240-index.html	Edgar Link	pending
0001477932-23-003240.txt	Edgar Link	pending
0001477932-23-003240-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vnrx-20230331.xsd	Edgar Link	pending
vnrx_10q.htm	Edgar Link	pending
vnrx-20230331_def.xml	Edgar Link	unprocessable
vnrx-20230331_pre.xml	Edgar Link	unprocessable
vnrx_ex311.htm	Edgar Link	pending
vnrx_ex312.htm	Edgar Link	pending
vnrx_ex321.htm	Edgar Link	pending
vnrx_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VNRX
VolitionRX Ltd Stock $vnrx

2023 Q2 Form 10-Q Financial Statement

#000147793223003240 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNRX VolitionRX Ltd Stock $vnrx

2023 Q2 Form 10-Q Financial Statement

#000147793223003240 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VNRX
VolitionRX Ltd Stock $vnrx